- |||||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Journal: Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients. (Pubmed Central) - Sep 28, 2023
P4
These findings could help clinicians choose the most appropriate treatment for their patients with ITP based on the phase of the disease. This trial is registered in clinicaltrials.gov with registration number NCT05861297.
- |||||||||| dexamethasone / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Surgery: MIDCAB (Mid-Calf Block) for Foot Surgery (clinicaltrials.gov) - Sep 28, 2023
P4, N=20, Completed,
Recruiting --> Completed Recruiting --> Completed | Trial completion date: Apr 2024 --> Nov 2022 | Trial primary completion date: Apr 2024 --> Nov 2022
- |||||||||| cevostamab (RG6160) / Roche, Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change, Trial completion date, Trial primary completion date: PLYCOM: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - Sep 28, 2023
P1/2, N=200, Recruiting,
The prospective GMMG-DANTE trial investigating DVd exclusively in r/rMM patients with severe RI showed efficacy and safety to be comparable to data from patients without RI. N=50 --> 200 | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Mar 2026
- |||||||||| dexamethasone / Generic mfg., fluocinolone acetonide / Generic mfg.
Journal: Treatment of Intermediate Uveitis-associated Retinal Vasoproliferative Tumors: A Case Series. (Pubmed Central) - Sep 27, 2023
The outcome of patients with SPS was generally favorable, but more aggressive immunotherapies are necessary for GAD65-positive patients with SPS. Combination intravitreal anti-VEGF and corticosteroid implants may be a useful approach for the treatment of intermediate uveitis-associated VPTs and can lead to both functional and structural improvement.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Characterizing steroid-refractory immunotherapy toxicities and effect of second-line immunosuppression on clinical outcomes (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1558;
Combination intravitreal anti-VEGF and corticosteroid implants may be a useful approach for the treatment of intermediate uveitis-associated VPTs and can lead to both functional and structural improvement. An electronic database search was performed for patients who received anti-PD-(L)1 and/or anti-CTLA-4 therapies for stage III-IV immunogenic (skin, GU, lung, GI) malignancies from 2013
- |||||||||| aspirin / Generic mfg., hydrocortisone / Generic mfg., ibuprofen / Generic mfg.
Journal: Self-Healing Oxalamide Organogelators of Vegetable Oil. (Pubmed Central) - Sep 27, 2023
The oxalamide gelators showed thermoreversible and thixotropic properties in vegetable oils with a minimum gelation concentration of just 0.025 wt%. The substitution of palm fats with gelled sunflower oil applied in cocoa and milk spreads at gelator concentrations lower than 0.2 wt% have shown promising viscoelastic properties compared to that of the original food products.
- |||||||||| dexamethasone / Generic mfg.
Journal, HEOR: Associations of physical activity and quality of life in parapneumonic effusion patients. (Pubmed Central) - Sep 27, 2023
This study is a secondary analysis of a randomised trial (dexamethasone versus placebo) for hospitalised patients with PPE...Moderate-to-vigorous physical activity participation was associated with higher QoL scores. Increasing moderate-to-vigorous physical activity following discharge from the hospital may be associated with improvements in QoL.
- |||||||||| dexamethasone injection / Generic mfg.
Journal, Real-world evidence, Real-world: Anterior segment complications after dexamethasone implantations:real world data. (Pubmed Central) - Sep 26, 2023
We observed that the patient's diagnosis did not cause a statistically significant change in the observation of side effects. As a result of our findings, close follow-up of IOP after the injection of dexamethasone implants would be appropriate.
- |||||||||| Wakix (pitolisant) / Ferrer International, Paragon Biosci, Sunosi (solriamfetol) / Axsome Therap, Pharmanovia
Review, Journal: Idiopathic hypersomnia and Kleine-Levin syndrome. (Pubmed Central) - Sep 26, 2023
KLS attenuates with time when starting during teenage, including less frequent and less severe episodes. Adequate sleep habits, avoidance of alcohol and infections, as well as lithium and sometimes valproate (off label, after agreement from reference centres) help reducing the frequency and severity of episodes, and IV methylprednisolone helps reducing long (>30d) episode duration.
- |||||||||| Tarpeyo (budesonide) / Calliditas, Stada
Journal: IgA nephropathy (Pubmed Central) - Sep 26, 2023
Nefecon (encapsulated budesonide) is the first specific drug licensed for treatment of high risk IgAN patients. A
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Journal: Association of monoclonal gammopathy of undetermined significance and C3 glomerulopathy. (Pubmed Central) - Sep 26, 2023
Here, we present the case of a patient with a prior diagnosis of MGUS who presented with proteinuria and microscopic haematuria and was diagnosed with C3 glomerulopathy. The patient had complete resolution of the disease after receiving treatment with a combination of dexamethasone, lenalidomide and bortezomib for the underlying MGUS.
- |||||||||| hydrocortisone / Generic mfg.
Preclinical, Journal: Sex-based impact of pancreatic islet stressors in GluCreERT2/Rosa26-eYFP mice. (Pubmed Central) - Sep 26, 2023
The present study examines differences in metabolic and pancreatic islet adaptative responses following streptozotocin (STZ) and hydrocortisone (HC) administration in male and female transgenic GluCreERT2/Rosa26-eYFP mice...The number of glucagon-positive alpha-cells altering their lineage to insulin-positive beta-cells was increased in male, but not female, STZ mice. Taken together, although there was no obvious sex-specific alteration of metabolic profile in STZ or HC mice, subtle differences in pancreatic islet morphology emphasises the impact of sex hormones on islets and importance of taking care when interpreting observations between males and females.
- |||||||||| fluocinolone acetonide / Generic mfg.
Review, Journal, Adverse events: Optimizing glucocorticoid therapy for Beh (Pubmed Central) - Sep 26, 2023
Moreover, we underscore the importance of combining GCS with immunosuppressive drugs and biological agents to minimize adverse reactions and optimize therapeutic outcomes. The review concludes that, while GCS remain a crucial component of BU treatment, careful consideration of their administration and combination with other therapies is essential to achieve long-term remission and improved visual outcomes for patients with BU.
- |||||||||| dexamethasone / Generic mfg.
Journal: Slc7a11 stimulates glutathione synthesis to preserve fatty acid metabolism in primary hepatocytes. (Pubmed Central) - Sep 26, 2023
Furthermore, direct treatment with reduced GSH or inhibition of ferroptosis is sufficient to drive protective effects on fatty acid metabolism in primary hepatocytes. Our results demonstrate that Slc7a11 expression in isolated primary hepatocytes induces GSH production, which protects against ferroptosis, to increase fatty acid metabolic gene expression, AKT and AMPK signaling and mitochondrial function in synergy with dexamethasone treatment, thereby efficiently preserving primary hepatocyte metabolic signatures, thus providing a promising approach to better reserve primary hepatocyte metabolic activities after isolation to potentially improve the understanding of liver biological functions from studies using primary hepatocytes.
- |||||||||| dexamethasone / Generic mfg., dexmedetomidine / Generic mfg.
Trial completion date, Trial primary completion date: Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block (clinicaltrials.gov) - Sep 26, 2023
P4, N=60, Recruiting,
Our results demonstrate that Slc7a11 expression in isolated primary hepatocytes induces GSH production, which protects against ferroptosis, to increase fatty acid metabolic gene expression, AKT and AMPK signaling and mitochondrial function in synergy with dexamethasone treatment, thereby efficiently preserving primary hepatocyte metabolic signatures, thus providing a promising approach to better reserve primary hepatocyte metabolic activities after isolation to potentially improve the understanding of liver biological functions from studies using primary hepatocytes. Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Dec 2023
- |||||||||| Xhance (fluticasone propionate intranasal spray) / OptiNose
Trial completion date, Trial primary completion date: OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps (clinicaltrials.gov) - Sep 26, 2023
P3, N=120, Recruiting,
Trial completion date: Feb 2028 --> Feb 2029 Trial completion date: Dec 2023 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Mar 2026
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg.
Trial completion: Maintenance Therapy With Subcutaneous Bortezomib (clinicaltrials.gov) - Sep 26, 2023
P2, N=63, Completed,
Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Aug 2023 | Trial primary completion date: Dec 2023 --> Aug 2023 Active, not recruiting --> Completed
- |||||||||| Veramyst (fluticasone furoate nasal spray) / GSK
Journal: Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19. (Pubmed Central) - Sep 25, 2023
P3
Treatment with inhaled fluticasone furoate for 14 days did not result in a shorter time to recovery than placebo among outpatients with Covid-19 in the United States. (Funded by the National Center for Advancing Translational Sciences and others; ACTIV-6 ClinicalTrials.gov number, NCT04885530.).
- |||||||||| dexamethasone / Generic mfg.
Journal: Influence of dexamethasone on the interaction between glucocorticoid receptor and SOX9: A molecular dynamics study. (Pubmed Central) - Sep 25, 2023
The outcome of this research could help the understanding of possible molecular interactions between GR and SOX9 and their role in the determination of cell fate. The results highlight the key residues at the interface between GR and SOX9 involved in the complexation process and shed light on the mechanism through which DEX modulates GR-SOX9 binding and exerts its biological activity.
- |||||||||| Filspari (sparsentan) / Travere Therap, CSL Behring
Journal: Diagnosis and Treatment of IgA Nephropathy-2023 (Pubmed Central) - Sep 24, 2023
New promising therapeutics are enteral Budesonide or the dual angiotensin-II-receptor- and endothelin-receptor-antagonist Sparsentan. Rapidly progressive IgAN should be treated with corticosteroids and cyclophosphamide like ANCA-associated vasculitis.
- |||||||||| dexamethasone injection / Generic mfg.
Review, Journal: Retinal artery occlusion after facial filler injection in a patient with patent foramen ovale: a case report and literature review. (Pubmed Central) - Sep 24, 2023
The patient was treated with intravenous dexamethasone and cobamamide, as well as extracorporeal counterpulsation therapy; this approach has not been described in previous literature regarding retinal artery occlusion...Moreover, patients undergoing hyaluronic acid injection should receive information regarding the potential for mild and severe complications; relevant tests should be performed before surgery to exclude vulnerable patients. Finally, a nursing system is needed to facilitate the emergency recognition, triage, and management of retinal artery occlusion.
- |||||||||| Sarclisa (isatuximab-irfc) / Sanofi, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
MODULE 2: Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM (Omni San Diego, Grand Ballroom (Level 2), 4) - Sep 23, 2023 - Abstract #ASH2023ASH_272;
Supported by AbbVie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Legend Biotech, Regeneron Pharmaceuticals Inc, and Sanofi. Key factors, such as age, choice of induction regimen, duration of response and comorbidities, in the selection and sequencing of therapy for patients who experience disease progression on induction or maintenance treatment Updated findings from the Phase III ICARIA-MM and IKEMA studies of isatuximab in combination with standard doublet regimens for R/R MM; FDA-approved indication for and optimal use of isatuximab Early results with and ongoing evaluation of various subcutaneous formulations of isatuximab Published efficacy and safety data supporting the use of selinexor in combination with a proteasome inhibitor, such as bortezomib or carfilzomib, for patients with R/R MM; optimal incorporation into clinical practice and practical considerations Early data with other selinexor-based combination strategies; ongoing Phase III XPORT-MM-031 trial of selinexor/pomalidomide/dexamethasone for patients who have received at least 1 prior therapy
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Magnetic Resonance Imaging Reflects Disease Activity in the (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4400;
Remission of vasculitic activity in cranial arteries took more than 24 weeks, which was longer than time to clinical symptom resolution and normalization of serum proteins but paralleled intima-media thickness measurements using ultrasound [4]. Thus, in contrast to large vessel signals and PMR findings, the dynamic of cranial vessel signals suggests that MRI of these arteries is a very promising monitoring tool for suspected relapse after 52 weeks of treatment.
|
